...Good afternoon, and thank you for joining us today. My name is John Quisel, and I'm the CEO here at Disc medicine. Today, we're going to discuss a disorder called Erythropoietic protoporphyria, also referred to as EPP. This is a rare and severe genetic disorder. And our drug development program for the molecule called Bitopertin is now in multiple Phase 2 trials to treat this disorder. Before I begin, I should note that we may be making forward-looking statements today. Each should be take about context with the language on the slide, as well as in our 10-K and other security filings. We've got an exciting program today. We're delighted to be joined by Professor Bruce Wang from University of California, San Francisco, and also Professor Jean-Charles Deybach, who joins us from Paris University and was the former head of the French Porphyria Centre. And then lastly, we'll have a presentation from Will Savage, the Chief Medical Officer here at Disc Medicine. First, I'll provide a background...
